TL;DR

Oral and injectable oestradiol are the same active hormone — 17β-oestradiol — but are not pharmacologically equivalent
Oral oestradiol has ~5% bioavailability due to first-pass hepatic metabolism, producing an unphysiological oestrone-to-oestradiol ratio
Injectable oestradiol (as ester prodrugs) avoids oral first-pass metabolism, producing higher oestradiol levels relative to dose and a metabolite ratio closest to physiological among the available routes
Oral oestradiol carries a higher VTE risk than transdermal; injectable data are limited but lower risk is biologically plausible
Testosterone suppression fails in a meaningful proportion of patients on oral regimens; injectable monotherapy shows promising suppression rates in emerging data

Oral and injectable oestradiol are the same active hormone — 17β-oestradiol — but they are not pharmacologically equivalent. The route of administration creates fundamentally different metabolic profiles, hepatic effects, and clinical outcomes. Understanding these differences matters when evaluating whether your HRT is working as well as it could.

The first-pass problem with oral oestradiol

When you swallow an oral oestradiol tablet, it is absorbed from the gut and passes directly to the liver via portal circulation before reaching systemic blood supply. This is the first-pass effect. Approximately 95% of oral oestradiol is converted during this process into oestrone and other conjugates with considerably weaker oestrogenic activity. The absolute bioavailability of oral micronised oestradiol is around 5%, with significant interindividual variability.

The result is an oestrone-to-oestradiol ratio that is markedly unphysiological. In premenopausal cisgender women, oestrone and oestradiol concentrations are generally of similar magnitude, producing ratios close to 1:1. A 2025 study measuring this directly in trans women on different routes of oestradiol found oral oestradiol produced the highest ratio (9.28), followed by sublingual (6.88); transdermal and injectable oestradiol were both substantially lower (2.22 and 0.84 respectively), with injectable coming closest to the cisgender physiological ratio. This means non-oral routes don’t fully replicate normal female physiology either — transdermal in particular still runs meaningfully above a true 1:1 ratio — but all non-oral routes produce oestrone-to-oestradiol ratios substantially closer to those seen in endogenous physiology than oral administration.

How injectable oestradiol differs

Injectable oestradiol — available as oestradiol valerate or oestradiol cypionate — is not oestradiol in solution. These are ester prodrugs suspended in oil, absorbed from a depot at the injection site and hydrolysed over time to release free 17β-oestradiol into the bloodstream. This process avoids oral portal first-pass hepatic metabolism, producing oestradiol levels much higher relative to dose and the oestrone-to-oestradiol ratio closest to endogenous physiology among currently available routes.

However, injectable oestradiol is not without variability. Levels can fluctuate substantially depending on dose, ester type, injection interval, timing of the blood draw relative to the last injection, and individual absorption from the depot. Injectable regimens can produce substantial peak–trough variation, making interpretation of serum oestradiol highly dependent on the timing of blood sampling. Injectables are not inherently steadier than other routes — transdermal formulations typically produce lower, more consistent levels over time. The advantage of injectables is the capacity to achieve higher peak oestradiol levels and, in many individuals, effective testosterone suppression — not greater pharmacokinetic predictability.

Transdermal oestradiol (patches, gels, sprays) similarly avoids first-pass hepatic metabolism. It produces steadier, generally lower peak levels than injections, and is often preferred for people with elevated cardiovascular or clotting risk.

Sublingual oestradiol partially bypasses first-pass metabolism via transmucosal absorption, though some oral swallowing typically occurs, so the bypass is incomplete.

VTE and cardiovascular risk

Oral oestradiol’s hepatic first-pass effect activates procoagulant pathways, and oral oestrogen has been associated with increased venous thromboembolism (VTE) risk in both cisgender and trans women — though the absolute risk remains low, and interpretation is complicated by formulation, age, smoking, and the use of older oestrogen types in some studies.

Transdermal oestradiol, by avoiding hepatic first-pass, does not appear to activate these coagulation pathways in the same way. In menopausal literature it is consistently preferred for people with elevated VTE risk, and this finding is biologically well-supported.

For injectable oestradiol, data are limited. Lower VTE risk than oral is biologically plausible given the absence of oral first-pass hepatic exposure — but this has not been formally established in adequately powered studies and should not be assumed.

Oral oestradiol also has greater effects on SHBG, angiotensinogen, and serum triglycerides than non-oral routes — effects that are relevant for ongoing cardiovascular monitoring.

Testosterone suppression

Achieving testosterone suppression to female reference range (below 50 ng/dL) is a primary goal of feminising HRT. Oral oestradiol regimens do not always achieve this. In one cohort of 98 transgender women treated with oral oestradiol and spironolactone, only the highest suppressing quartile reliably achieved testosterone in the female range (mean 27 ng/dL); the remaining three-quarters showed substantial reductions from baseline but did not consistently reach the <50 ng/dL guideline target. A separate, frequently cited analysis found approximately two-thirds of patients on oestradiol plus spironolactone achieved female-range testosterone suppression — meaning around one-third did not.

Injectable oestradiol monotherapy — without a separate antiandrogen — has shown promising results in emerging data. A 2025 study found testosterone suppression to target range in 82.6% of patients on injectable oestradiol alone. However, comparative trial data between oral and injectable regimens in trans women remain limited, and injectables do not uniformly outperform oral regimens across all patients and contexts.

Route of administration is one variable among several — alongside antiandrogen choice, dose, and individual response — that determines suppression outcomes. If testosterone is not suppressing adequately on your current regimen, route is a clinically meaningful variable to discuss with your prescriber.

⚠️ Clinical note: The VTE data cited primarily reflects oral vs transdermal comparisons in cisgender and trans women. Injectable VTE risk data are insufficient to draw firm conclusions. Individual risk assessment should account for personal history, smoking, BMI, and formulation.

Sources

Liang JJ, Jolly D, Chan KJ, Safer JD. Testosterone Levels Achieved by Medically Treated Transgender Women in a United States Endocrinology Clinic Cohort. Endocrine Practice. 2018;24(2):135–142.
Misakian AL, Ariel D, Sullivan EA, Singh G, Loeb D, Strickland T, Iwamoto SJ, Rothman MS, Botzheim B, Liang JW, Kelley C, Hamnvik OR. Injectable Estradiol Monotherapy Effectively Suppresses Testosterone in Gender-Affirming Hormone Therapy. Endocrine Practice. 2025;31(11).
Kariyawasam NM, Ahmad T, Sarma S, Fung R. Comparison of Estrone/Estradiol Ratio and Levels in Transfeminine Individuals on Different Routes of Estradiol. Transgender Health. 2025.
King H, Kelley TP, Shatzel JJ. Gender-Affirming Hormone Therapy in the Transgender Patient: Influence on Thrombotic Risk. Hematology, American Society of Hematology Education Program. 2024;2024(1):652–663.